Form 4: IO Biotech Director Peter Hirth Acquires Stock Options

Director Peter Hirth acquired 45,642 stock options in IO Biotech, Inc. on June 6, 2024.

Summary

• Peter Hirth, a director of IO Biotech, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on June 6, 2024.
• Hirth acquired 45,642 stock options with an exercise price of $1.25.
• These options vest on June 6, 2025, contingent upon continued service and accelerate fully upon a change of control.
• Following the transaction, Hirth directly owns 45,642 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard insider transaction report. The acquisition of options by a director is generally viewed as a slightly positive sign, but it's not a major event.

Positives

• A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC when company insiders, such as directors and officers, trade in their company's securities. These filings provide transparency to the market regarding insider transactions.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a company director.

Key Dates